AI Generated
Jul 2, 2026, 10:29
Nisar Ahmed: The Evolution of Anticoagulation Therapy
Nisar Ahmed, Pharmacist at Zubair Pharmacy, shared a post on LinkedIn:
“70 years of warfarin vs the new generation.
Here’s why anticoagulation has changed forever.
Warfarin — blocks vitamin K clotting factors, needs constant INR monitoring, dozens of food and drug interactions.
Still irreplaceable for mechanical heart valves.
Apixaban (Eliquis) — directly inhibits Factor Xa, predictable, no monitoring, fewer interactions.
The landmark ARISTOTLE trial: 21% less stroke, 31% less major bleeding, 11% lower mortality vs warfarin in AF.
- Mechanical heart valve? Stick with warfarin – DOACs are contraindicated.
- Non-valvular AF or VTE? Apixaban is now the standard of care.
- Full breakdown in the infographic . “
Stay updated with Hemostasis Today.
-
Oct 11, 2026, 22:40Bahram Alamdary Badlou: Platelets as First Responders in Hemostasis, Immunity, and Inflammation
-
Oct 11, 2026, 22:22Vipin Singh: New Publication on Hippo-YAP Signaling and Platelet Activation
-
Oct 11, 2026, 22:21Trygve Berge: New AFNOR Paper on AF-related Stroke in Norway
-
Oct 11, 2026, 22:09Omar Alomari: Our New Publication on Apixaban vs Rivaroxaban for VTE
-
Oct 11, 2026, 21:22Shayan Roshan: Happy to Share Two Research Milestones in Trauma Care and Pancreatic Cancer
-
Oct 11, 2026, 21:16Chokri Ben Lamine: Anemia in Myelofibrosis – Multiple Mechanisms, Limited Responses
-
Oct 11, 2026, 21:03Carmela Walker: Supporting Warriors Living With SCD Through Dental Care and Advocacy
-
Oct 11, 2026, 21:00Rishdha Roshad: Intraoperative Cell Salvage – Turning Blood Loss into an Opportunity for Recovery
-
Oct 11, 2026, 20:59Anthony R. Sloan: Honored to Share Our Work at the 20th Midwest Platelet Conference